US pharma major AbbVie (NYSE: ABBV) has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL).
The findings, which were presented at the 2016 American Society of Oncology (ASCO) Annual Meeting, include an analysis of outcomes from the RESONATE and RESONATE-2 trials, which showed Imbruvica was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy.
Other data includes first-ever follow-up data from the HELIOS trial, which showed that Imbruvica in combination with bendamustine and rituximab (BR) continued to demonstrate superiority over time versus placebo plus BR in relapsed/refractory CLL/SLL patients. Improvements in quality of response were also noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze